Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Fusion Pharmaceuticals Inc FUSN

Healthcare Biotechnology
Fusion Pharmaceuticals Inc. is a clinical-stage oncology company. The Company is focused on developing radiopharmaceuticals as precision medicines. It has developed its Targeted Alpha Therapies (TAT), platform to enable it to connect alpha particle emitting isotopes to various targeting molecules to selectively deliver the alpha particle payloads to tumors. The TAT platform is underpinned by... see more

Recent & Breaking News (NDAQ:FUSN)

Fusion Pharmaceuticals Announces Fourth Quarter 2022 Financial Results and Clinical Program Updates

PR Newswire March 16, 2023

Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire March 8, 2023

Fusion Pharmaceuticals to Present at the 43rd Annual Cowen Healthcare Conference

PR Newswire March 2, 2023

Fusion Pharmaceuticals to Acquire Phase 2 Program for 225Ac-PSMA I&T, a Radiopharmaceutical Targeting Metastatic Castrate Resistant Prostate Cancer

PR Newswire February 13, 2023

Fusion Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference

PR Newswire February 13, 2023

Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire February 7, 2023

Fusion Pharmaceuticals Reports Progress and Provides Recent Corporate Highlights

PR Newswire January 6, 2023

Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Canada NewsWire January 4, 2023

Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire December 7, 2022

Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire November 9, 2022

Fusion Pharmaceuticals Announces Third Quarter 2022 Financial Results and Clinical Program Updates

PR Newswire November 8, 2022

Fusion Pharmaceuticals Appoints Dmitri Bobilev, M.D. as Chief Medical Officer

PR Newswire November 7, 2022

Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire October 5, 2022

Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire September 13, 2022

Fusion Pharmaceuticals to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

PR Newswire September 7, 2022

Fusion Pharmaceuticals Announces First Patient Dosed in Phase 1/2 Study of FPI-1966 In Patients with Advanced Solid Tumors Expressing FGFR3

PR Newswire August 29, 2022

Fusion Pharmaceuticals Announces Second Quarter 2022 Financial Results and Clinical Program Updates

PR Newswire August 9, 2022

Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire August 2, 2022

Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire July 7, 2022

Fusion Pharmaceuticals Announces FDA Clearance of IND for FPI-2059, an Investigational Small Molecule-Based Radiopharmaceutical Targeting Solid Tumors Expressing NTSR1

PR Newswire June 23, 2022